胰腺导管腺癌白皮书:美国腹部放射学会胰腺导管腺癌疾病聚焦专家组第一部分,AJCC分期系统、NCCN指南及交界可切除疾病
本文综述胰腺导管腺癌AJCC第8版TNM分期(侧重预后评估)与NCCN指南(2.2019版,2019年4月9日)基于肿瘤-血管关系的可切除性三分类(可切除、交界可切除、不可切除),并讨论交界可切除PDAC定义演变中的挑战与争议。
要点
- AJCC第8版PDAC分期系统的重点已从指导治疗转向评估预后。
- NCCN指南依据肿瘤与血管关系将PDAC分为可切除、交界可切除和不可切除三类。
- 交界可切除PDAC的定义随时间演变,不同学会间存在差异,需熟悉更新标准。
核心结论
- 准确分期是制定PDAC分期特异性治疗方案的重要初始步骤。
- AJCC第8版TNM分期侧重评估预后,而NCCN指南基于肿瘤-血管关系定义可切除性以指导治疗。
- 交界可切除PDAC的定义随时间和不同学会而变化,其标准、治疗及随访推荐存在争议。
研究设计与样本
- 美国腹部放射学会胰腺导管腺癌疾病聚焦专家组发布的白皮书,综述AJCC第8版分期、NCCN指南(2.2019版,2019年4月9日)及交界可切除PDAC的挑战与争议。
诊断标准与关键数值
- NCCN指南基于肿瘤-血管关系将PDAC可切除性分为可切除、交界可切除和不可切除三类。
- AJCC第8版TNM分期系统用于PDAC分期,其重点为评估预后。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive gastrointestinal malignancy with a poor 5-year survival rate. Accurate staging of PDAC is an important initial step in the development of a stage-specific treatment plan. Different staging systems/consensus statements convened by different societies and academic practices are currently used. The most recent version of the American Joint Committee on Cancer (AJCC) tumor/node/metastases (TNM) staging system for PDAC has shifted its focus from guiding management to assessing prognosis. In order to preoperatively define the resectability of PDAC and to guide management, additional classification systems have been developed. The National Comprehensive Cancer Network (NCCN) guidelines, one of the most commonly used systems, provide recommendations on the management and the determination of resectability for PDAC. The NCCN divides PDAC into three categories of resectability based on tumor-vessel relationship: 'resectable,' 'borderline resectable,' and 'unresectable'. Among these, the borderline disease category is of special interest given its evolution over time and the resulting variations in the definition and the associated recommendations for management between different societies. It is important to be familiar with the evolving criteria, and treatment and follow-up recommendations for PDAC. In this article, the most current AJCC staging (8th edition), NCCN guidelines (version 2.2019-April 9, 2019), and challenges and controversies in borderline resectable PDAC are reviewed.
引用
- Kulkarni NM, Soloff EV, Tolat PP, et al. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease. Abdom Radiol (NY). 2020. PMID: 31748823. doi:10.1007/s00261-019-02289-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。